 | |
| Clinical data | |
|---|---|
| Trade names | Yupelri |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619009 |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C35H43N5O4 |
| Molar mass | 597.760 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Revefenacin, sold under the brand nameYupelri, is amedication for the treatment ofchronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It wasdeveloped by Theravance Biopharma and is marketed byMylan. Revefenacin isformulated as a solution that isnebulized and inhaled.[2]
Revefenacin is abronchodilator that exerts its effect as a long-actingmuscarinic antagonist.[3]
In some countries, Yupelri is marketed byViatris after Upjohn merged with Mylan to create Viatris.[4][5]
